Did you mean 3.2.1 4s 5?
Displaying drugs 6526 - 6550 of 12370 in total
MDX-018
MDX-018, also known as HuMax-Inflam, is a fully human antibody that is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation. Trials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. Other possible indications include chronic obstructive pulmonary disease (COPD)...
Investigational
FX06
FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc.
Investigational
AGS-004
AGS-004 is a personalized RNA-loaded dendritic cellbased
immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden. Non-personalized HIV immunotherapies are unable to raise cytotoxic T lymphocytes against HIV antigens, fail to induce T cell memory, and, most importantly, do...
Investigational
RP01
RP01 is a novel anti-IgE immunotherapy for allergic individuals. It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. It could offer benefit to millions of asthma and allergy patients.
Investigational
ZEN-012
ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors.
Investigational
AIT-034
AIT-034 is a distinct chemical analog of hypoxanthine and pyrollidone that has been demonstrated in animal studies to enhance memory and to reverse memory deficits in severely impaired animals that do not respond to Neotrofin. AIT-034 does not induce the production of NGF, and its mechanism of action is therefore...
Investigational
Matched Iupac: … 3-(6-oxo-6,9-dihydro-3H-purin-9-yl)-N-[3-(2-oxopyrrolidin-1-yl)propyl]propanamide …
K-00546
Experimental
Matched Synonyms: … CDK1/2 inhibitor III …
Matched Iupac: … 5-amino-N-(2,6-difluorophenyl)-3-[(4-sulfamoylphenyl)amino]-1H-1,2,4-triazole-1-carbothioamide …
Matched Iupac: … 5-amino-N-(2,6-difluorophenyl)-3-[(4-sulfamoylphenyl)amino]-1H-1,2,4-triazole-1-carbothioamide …
MK-0731
MK-0731 is a kinesin spindle protein inhibitor and antineoplastic agent.
Experimental
Matched Iupac: … (2S)-4-(2,5-difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2- …
MK-0249
MK0249 has been used in trials studying the treatment of Hypopnea Syndrome, Alzheimer's Disease, Paranoid Schizophrenia, Sleep Apnea, Obstructive, and Excessive Daytime Sleepiness, among others.
Investigational
Matched Iupac: … 2-methyl-3-{4-[3-(pyrrolidin-1-yl)propoxy]phenyl}-5-(trifluoromethyl)-3,4-dihydroquinazolin-4-one …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
MK-0777
MK-0777 has been used in trials studying the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder.
Investigational
Matched Iupac: … 5-({[7-tert-butyl-3-(2-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]oxy}methyl)-1-ethyl-1H-1,2,4 …
AKN-028
AKN-028 has been used in trials studying the treatment of Acute Myeloid Leukemia.
Investigational
Matched Iupac: … N2-(1H-indol-5-yl)-6-(pyridin-4-yl)pyrazine-2,3-diamine …
MK-0752
Mk 0752 is under investigation in clinical trial NCT00572182 (MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer).
Investigational
Matched Iupac: … 3-[(1s,4r)-4-(4-chlorobenzenesulfonyl)-4-(2,5-difluorophenyl)cyclohexyl]propanoic acid …
MK-0533
MK-0533 is under investigation in clinical trial NCT00543959 (Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)).
Investigational
Matched Iupac: … (2R)-2-{3-[3-(4-methoxybenzoyl)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]phenoxy}butanoic acid …
Matched Description: … investigation in clinical trial NCT00543959 (Efficacy and Tolerability of MK0533 in Patients With Type 2 …
Matched Description: … investigation in clinical trial NCT00543959 (Efficacy and Tolerability of MK0533 in Patients With Type 2 …
CYP-001
CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are then able to differentiate into bone, cartilage, and adipose tissue.
The MCA-derived MSCs can be obtained from induced pluripotent...
Investigational
Matched Description: … When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes …
MK-0773
MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)).
Investigational
Matched Iupac: … (4aS,4bS,6aS,7S,9aS,9bS,11aR)-3-fluoro-N-({1H-imidazo[4,5-b]pyridin-2-yl}methyl)-1,4a,6a-trimethyl-2- …
IN01
The IN01 Vaccine, sponsored by the Instituto Oncologico Dr Rosell, IN3BIO, and PANGAEA, is a compound containing recombinant bacteria . These cultures contain EGF-4-EGF with the cholera toxin B-subunit domain G33D sequence . Administration of the vaccine stimulates the production of anti-epidermal growth factor (anti-EGF) neutralizing antibodies . Of note,...
Investigational
Matched Description: … These cultures contain EGF-4-EGF with the cholera toxin B-subunit domain G33D sequence[L30543]. ... Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 …
MK-0482
MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.
Investigational
Matched Description: … 0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3. …
KF-0210
KF-0210 is a small molecule developed by Keythera Pharmaceuticals. It is being investigated for cancers.
Investigational
GEN-001
Investigational
AMT-080
AMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.
Investigational
ALX-009
Investigational
BSG-005
Investigational
TLY-012
TLY-012 is a PEGylated recombinant human tumor necrosis factor-related apoptosis-inducing ligand (PEGylated TRAIL).
Investigational
Displaying drugs 6526 - 6550 of 12370 in total